Top-line phase 2b study results

Stockholm 8th September, 2015. – The Board of Peptonic Medical (publ)  - a company developing pharmaceuticals based on oxytocin – today announced that it has reviewed the un-blinded clinical data of the phase 2b study of Vagitocin® (oxytocin) in the treatment of Vaginal Atrophy in post-menopausal women.

The study did not meet its clinical endpoints, because all treatment groups, including the placebo, showed the same statistically significant improvement in both subjective and objective parameters.

The board cannot explain how placebo can have an equal positive effect as active drug, and has therefore concluded, that before publishing the data, a thorough investigation needs to be conducted. It is anticipated that the data will be published by the end of September 2015.

For more information, please contact;
Johan Inborr, CEO
Telephone:  +46 708 853 893

E-mail: johan.inborr@peptonicmedical.se

About Peptonic Medical AB

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Peptonic Medical’s mission is to develop safe and effective drugs based on the well-known beneficial properties of oxytocin.